Sunmax Biotechnology Co., Ltd. (TPEX:4728)

Market Cap	15.79B
Revenue (ttm)	1.74B
Net Income (ttm)	698.95M
Shares Out	54.46M
EPS (ttm)	12.82
PE Ratio	22.62
Forward PE	n/a
Dividend	11.00 (3.79%)
Ex-Dividend Date	n/a

Volume	23,752
Average Volume	17,457
Open	289.00
Previous Close	289.00
Day's Range	289.00 - 291.00
52-Week Range	199.00 - 350.00
Beta	0.25
RSI	57.85
Earnings Date	Mar 27, 2025

About Sunmax Biotechnology

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4728

Financial Performance

In 2023, Sunmax Biotechnology's revenue was 1.69 billion, an increase of 20.64% compared to the previous year's 1.40 billion. Earnings were 625.71 million, an increase of 17.21%.